The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study
Open accessAbstract
Objective: To investigate the association between SARS-CoV-2 vaccination and myocarditis or myopericarditis. Design: Population based cohort study. Setting: Denmark. Participants: 4 931 775 individuals aged 12 years or older, followed from 1 October 2020 to 5 October 2021. Main outcome measures: The primary outcome, myocarditis or myopericarditis, was defined as a combination of a hospital diagnosis of myocarditis or pericarditis, increased troponin levels, and a hospital stay lasting more than 24 hours. Follow-up time before vaccination was compared with follow-up time 0-28 days from the day of vaccination for both first and second doses, using Cox proportional hazards regression with age as an underlying timescale to estimate hazard ratios adjusted for sex, comorbidities, and other potential confounders. Results: During follow-up, 269 participants developed myocarditis or myopericarditis, of whom 108 (40%) were 12-39 years old and 196 (73%) were male. Of 3 482 295 individuals vaccinated with BNT162b2 (Pfizer-BioNTech), 48 developed myocarditis or myopericarditis within 28 days from the vaccination date compared with unvaccinated individuals (adjusted hazard ratio 1.34 (95% confidence interval 0.90 to 2.00); absolute rate 1.4 per 100 000 vaccinated individuals within 28 days of vaccination (95% confidence interval 1.0 to 1.8)). Adjusted hazard ratios among female participants only and male participants only were 3.73 (1.82 to 7.65) and 0.82 (0.50 to 1.34), respectively, with corresponding absolute rates of 1.3 (0.8 to 1.9) and 1.5 (1.0 to 2.2) per 100 000 vaccinated individuals within 28 days of vaccination, respectively. The adjusted hazard ratio among 12-39 year olds was 1.48 (0.74 to 2.98) and the absolute rate was 1.6 (1.0 to 2.6) per 100 000 vaccinated individuals within 28 days of vaccination. Among 498 814 individuals vaccinated with mRNA-1273 (Moderna), 21 developed myocarditis or myopericarditis within 28 days from vaccination date (adjusted hazard ratio 3.92 (2.30 to 6.68); absolute rate 4.2 per 100 000 vaccinated individuals within 28 days of vaccination (2.6 to 6.4)). Adjusted hazard ratios among women only and men only were 6.33 (2.11 to 18.96) and 3.22 (1.75 to 5.93), respectively, with corresponding absolute rates of 2.0 (0.7 to 4.8) and 6.3 (3.6 to 10.2) per 100 000 vaccinated individuals within 28 days of vaccination, respectively. The adjusted hazard ratio among 12-39 year olds was 5.24 (2.47 to 11.12) and the absolute rate was 5.7 (3.3 to 9.3) per 100 000 vaccinated individuals within 28 days of vaccination. Conclusions: Vaccination with mRNA-1273 was associated with a significantly increased risk of myocarditis or myopericarditis in the Danish population, primarily driven by an increased risk among individuals aged 12-39 years, while BNT162b2 vaccination was only associated with a significantly increased risk among women. However, the absolute rate of myocarditis or myopericarditis after SARS-CoV-2 mRNA vaccination was low, even in younger age groups. The benefits of SARS-CoV-2 mRNA vaccination should be taken into account when interpreting these findings. Larger multinational studies are needed to further investigate the risks of myocarditis or myopericarditis after vaccination within smaller subgroups.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Ammirati, E., Cavalotti, C., Milazzo, A., Pedrotti, P., Soriano, F., Schroeder, J. W., Morici, N., Giannattasio, C., Frigerio, M., Metra, M., et al. (2021) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2021.100774 · Cited by 86
RetractedThe Danish Civil Registration System as a tool in epidemiology
Schmidt, M., Pedersen, L., & Sørensen, H. T. (2014) · European Journal of Epidemiology · doi:10.1007/s10654-014-9930-3 · Cited by 3,441
Self-citationSchmidt, M., Schmidt, S. A. J., Adelborg, K., Sundbøll, J., Laugesen, K., Ehrenstein, V., & Sørensen, H. T. (2019) · Clinical Epidemiology · doi:10.2147/clep.s179083 · Cited by 1,379
Self-citationSafety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
Barda, N., Dagan, N., Ben-Shlomo, Y., Kepten, E., Waxman, J., Ohana, R., Hernán, M. A., Lipsitch, M., Kohane, I., Netzer, D., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110475 · Cited by 1,027
Sundbøll, J., Adelborg, K., Munch, T., Frøslev, T., Sørensen, H. T., Bøtker, H. E., & Schmidt, M. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-012832 · Cited by 834
Self-citationLong COVID in a prospective cohort of home-isolated patients
Blomberg, B., Mohn, K. G.-I., Brokstad, K. A., Zhou, F., Linchausen, D. W., Hansen, B.-A., Lartey, S., Onyango, T. B., Kuwelker, K., Sævik, M., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01433-3 · Cited by 659
Surveillance for Adverse Events After COVID-19 mRNA Vaccination
Klein, N. P., Lewis, N., Goddard, K., Fireman, B., Zerbo, O., Hanson, K. E., Donahue, J. G., Kharbanda, E. O., Naleway, A., Nelson, J. C., et al. (2021) · JAMA · doi:10.1001/jama.2021.15072 · Cited by 626
Myocarditis after Covid-19 Vaccination in a Large Health Care Organization
Witberg, G., Barda, N., Hoss, S., Richter, I., Wiessman, M., Aviv, Y., Grinberg, T., Auster, O., Dagan, N., Balicer, R. D., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110737 · Cited by 613
Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel
Mevorach, D., Anis, E., Cedar, N., Bromberg, M., Haas, E. J., Nadir, E., Olsha-Castell, S., Arad, D., Hasin, T., Levi, N., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2109730 · Cited by 599
Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military
Montgomery, J., Ryan, M., Engler, R., Hoffman, D., McClenathan, B., Collins, L., Loran, D., Hrncir, D., Herring, K., Platzer, M., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.2833 · Cited by 536
Cited by
Gluckman, T. J., Bhave, N. M., Allen, L. A., Chung, E. H., Spatz, E. S., Ammirati, E., Baggish, A. L., Bozkurt, B., Cornwell, W. K., Harmon, K. G., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.02.003 · Cited by 389
SARS-CoV-2 vaccination and myocarditis in a Nordic cohort study of 23 million residents
Karlstad, Ø., Hovi, P., Husby, A., Härkänen, T., Selmer, R. M., Pihlström, N., Hansen, J. V., Nohynek, H., Gunnes, N., Sundström, A., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.0583 · Cited by 221
Self-citationHeidecker, B., Dagan, N., Balicer, R., Eriksson, U., Rosano, G., Coats, A., Tschöpe, C., Kelle, S., Poland, G. A., Frustaci, A., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2669 · Cited by 159
Alami, A., Krewski, D., Farhat, N., Mattison, D., Wilson, K., Gravel, C. A., Farrell, P. J., Crispo, J. A. G., Haddad, N., Perez-Lloret, S., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-065687 · Cited by 44
Evolution in the Diagnosis and Treatment of Myocarditis in Recent Years: State of the Art
Campodonico, J., Lauri, C., Pezzuto, B., Agostoni, P., & Vignati, C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14217661 · Cited by 6
Metadata
- Authors
- Husby, A., Hansen, J. V., Fosbøl, E., Thiesson, E. M., Madsen, M., Thomsen, R. W., Sørensen, H. T., Andersen, M., Wohlfahrt, J., Gislason, G., Torp-Pedersen, C., Køber, L., & Hviid, A.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2021-12-16
- Volume
- 375
- Pages
- e068665
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W4200563579
- Cited by
- 275
- References
- 17
- FWCI
- 36.20
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study. https://app.cochat.ai/papers/10.1136/bmj-2021-068665
- The paper
- Husby, A., Hansen, J. V., Fosbøl, E., Thiesson, E. M., Madsen, M., Thomsen, R. W., Sørensen, H. T., Andersen, M., Wohlfahrt, J., Gislason, G., Torp-Pedersen, C., Køber, L., & Hviid, A. (2021). SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study. BMJ. https://doi.org/10.1136/bmj-2021-068665
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.